As of April 2024, the World Health Organization (WHO) has determined that nearly all circulating SARS-CoV-2 variants reported in publicly available databases are JN.1 derived coronavirus variants.
On April 26, 2024, the WHO stated in a media release that virus evolution is expected to continue from JN.1, and future formulations of COVID-19 vaccines should aim to induce enhanced neutralizing antibody responses to JN.1 and its descendent lineages.
The WHO says the regular review of the available vaccine effectiveness evidence (VE) is critical to assessing future versions.
Read More
